CLINICAL TRIALS PROFILE FOR BASMISANIL
Clinical Trials for Basmisanil
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02534207 ↗ | Basmisanil Positron Emission Tomography Study in Japanese Volunteers | Completed | Hoffmann-La Roche | Phase 1 | This study will evaluate the relationship between basmisanil plasma concentrations and the occupancy of Gamma-Amino Butyric Acid A (GABAA) receptor subtypes containing an alpha5 (α5) subunit in healthy Japanese volunteers. Each participant will have two post-screening imaging sessions. In the first imaging session, participants will have a baseline Positron Emission Tomography (PET) scan. In the second imaging session, participants will receive a single oral dose of basmisanil, followed by two on-treatment PET scans at about 4 and 10 hours post-dose. |
| NCT02928393 ↗ | A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke | Terminated | Hoffmann-La Roche | Phase 2 | This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke. |
| NCT02953639 ↗ | A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics | Completed | Hoffmann-La Roche | Phase 2 | This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics. |
| NCT05307679 ↗ | A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children With Dup15q Syndrome | Not yet recruiting | Hoffmann-La Roche | Phase 2 | This study will evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of basmisanil treatment in children with Dup15q syndrome aged 2 to 11 years. The study will test the hypothesis that modulation of a GABAA receptor subtype can address excessive receptor function and positively impact core neurodevelopmental disease features in children with Dup15q syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Basmisanil
Condition Name
Clinical Trial Locations for Basmisanil
Trials by Country
Clinical Trial Progress for Basmisanil
Clinical Trial Phase
Clinical Trial Sponsors for Basmisanil
Sponsor Name
